AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation ...
The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.
Chinese biopharma Hutchmed today announced that the Center for Drug Evaluation of China’s National Medical Products ...
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...
Limited (HCM) announced that the Center for Drug Evaluation of Chinas National Medical Products Administration or ...
Developed alongside AstraZeneca, the breakthrough designation comes following early pooled results from two ongoing trials ...
US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC: Cambridge, UK Tuesday, December 10, 2024 ...
12月6日至8日，备受瞩目的2024年欧洲肿瘤内科学会亚洲年会（ESMO Asia）在新加坡隆重举行。此次会议聚焦肿瘤研究的最新进展，吸引了亚洲乃至全球肿瘤学界的广泛关注。值得关注的是，LAURA 研究在本次 ESMO Asia ...
Summit Therapeutics shows promising results in Phase III trials for ivonescimab as a potential treatment for advanced NSCLC.
AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...
6d
A pooled analysis of the TROPION-Lung05 phase 2 and the TROPION-Lung01 phase 3 trials showed that Daiichi Sankyo (DSKYF.PK) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback